Congenital infection with cytomegalovirus (CMV) can induce immune responses and placental damage. By use of immunoassay panels, 27 cytokines were assessed in midtrimester amniotic fluid from 8 patients with congenital CMV, in midtrimester sera from 12 pregnant women with primary CMV infection, and in amniotic fluid and serum from uninfected maternal controls. Levels of the cytokines tumor necrosis factor a, interleukin 1b, interleukin 12, and interleukin 17; the chemokines CCL2, CCL4, and CXCL10; and the growth factors granulocyte-macrophage colony-stimulating factor and platelet-derived growth factor bb were significantly elevated in amniotic fluid from congenital CMV patients (P < .01). Only CXCL10 was significantly higher in sera from CMV-infected pregnant women. CMV infection during pregnancy is associated with a shift in cytokine expression toward a proinflammatory state.
Cytomegalovirus (CMV) is the leading cause of congenital infection, occurring in 0.3%-0.7% of live births [1] . Approximately 10%-15% of congenitally infected newborns have detectable manifestations, most commonly sensorineural hearing loss, organomegaly, microcephaly, intracranial calcification, and chorioretinitis, resulting from direct viral cytopathic effect on the fetus [2] . CMV infection of the fetus requires placental infection, followed by transplacental movement of the virus through syncytiotrophoblasts, cytotrophoblasts, and endothelial cells [3] . Infection of these cells is accompanied by inflammation, leukocyte infiltration, and induction of cytokines, all of which contribute to placental and fetal damage [3] . The extent to which virus-induced damage to the placenta contributes to fetal injury is uncertain, although it is becoming more evident that CMV promotes villitis, deciduitis, and tissue ischemia, which are all associated with adverse fetal outcomes [4, 5] .
Cytokines have an important role in establishing and maintaining a healthy pregnancy. The pattern of cytokine production during pregnancy is linked to placental maturation and 3 definable immunological phases [6] . A proinflammatory environment promoting cytotrophoblast invasion and placentation occurs in early pregnancy (T1), followed by T-helper cell 2 (Th2)/T-helper cell 1 (Th1) balance and immune tolerance during midpregnancy (T2), with a Th1 cytokine bias during the final stages of pregnancy in preparation for birth [6] . The balance of Th1/Th2 cytokines during T2 is reflected in amniotic fluid levels [7] , which are primarily placentally derived, rather than fetally derived, prior to 20 weeks of gestation.
Recent evidence suggests infection with CMV changes the Th1/Th2 balance during pregnancy through altered cytokine expression in placental cells [8] and increased expression of Th1 cytokines in amniotic fluid [9] . In the absence of infection, altered placental cytokine expression is associated with intrauterine growth restriction, prematurity, and early membrane rupture [10] . It is plausible that CMV-induced changes in cytokine levels result in proinflammatory changes in the placenta, with important consequences for placental development, placental function, virus transmission, and fetal viability. We compared cytokine expression in amniotic fluid from pregnancies with congenital CMV infection with that in specimens from uninfected controls.
MATERIALS AND METHODS

Congenital CMV Cases
Study samples were collected with consent from patients and with approval from the following ethics committees: South [11] . Pathogen-specific serology (IgG seroconversion and IgM) showed that none of these women had a recent or concurrent primary infection with herpes simplex virus (HSV) 1 or HSV-2, varicella-zoster virus, Toxoplasma gondii, parvovirus B19, rubella virus, enterovirus, or hepatitis C virus. Multiplex PCR of amniotic fluid and maternal serum samples were negative for (1) CMV, HSV-1 and HSV-2, varicella-zoster virus, T. gondii, and parvovirus B19; (2) rubella virus, enterovirus, hepatitis C virus, and lymphocytic choriomeningitis virus; (3) human herpesvirus (HHV) 6 , HHV-7, and HHV-8; and (4) Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum [11, 12] . Amniotic fluid and serum samples were frozen at 280°C prior to cytokine analyses.
Control Samples
Cytokine levels were also analyzed in 100 amniotic fluid and 33 serum samples collected from consenting, CMV-uninfected, pregnant women who received antenatal care during September 2003-January 2005, as described elsewhere [7] ; ethics approval was received from SESIAHS HREC (02/026 and 04/210) and UNSW HREC (04199). Serum samples were collected at the time of amniocentesis or at antenatal clinic visits at 11-37 weeks of gestation (median, 28 weeks). These pregnancies were not complicated by infection, as determined by pathogen-specific serology of serum and by multiplex PCR of amniotic fluid, as described above [11, 12] .
Measurement of Cytokine Levels in Amniotic Fluid and Maternal Sera
Concentrations of 27 cytokines were measured in 108 specimens of amniotic fluid (8 congenital CMV cases; 100 controls) and 45 specimens of maternal sera (12 congenital CMV cases; 33 controls), using a multiplex immunoassay (Bio-Plex Human 27-Plex Cytokine Panel and Reagent Kits, Bio-Rad) according to the manufacturer's instructions. Measurement was undertaken of the cytokines interferon c, interleukin 1b (IL-1b), interleukin 1 receptor antagonist (IL-1ra), interleukin 2, interleukin 4 (IL-4), interleukin 5, interleukin 6 (IL-6), interleukin 7, interleukin 9, interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), interleukin 17 (IL-17), and tumor necrosis factor a (TNF-a); the chemokines CXCL8, CXCL10, CCL2, CCL3, CCL4, CCL5, and CCL11; and the growth factors fibroblast growth factor, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), platelet-derived growth factor bb (PDGF-bb), and vascular endothelial growth factor [7] .
Statistical Analysis
Cytokine levels from congenital CMV infection cases and uninfected control subjects were compared in univariate analyses using the Mann-Whitney U test. An arbitrary cytokine level corresponding to the lower limit of detection was assigned when the cytokine level was undetectable. Given the multiple comparisons, statistical significance was defined as a P value of ,.01.
Alteration in cytokine levels in amniotic fluid samples from CMV-infected and CMV-uninfected women was assessed by heat map analysis and partial least squares analysis, using the R statistical package (available at: http://www. r-project.org/). Null data points were moved using the na.omit functions in R, removing patient samples containing null values. For the heat map analysis, the Spearman correlation in cytokine expression between each pair of samples was calculated, and complete linkage was used to cluster the samples [13] . Cytokine concentrations were used as linear variables. The heat map was generated using gplots in R. Generalized partial least squares analysis [14, 15] was used to find cytokines indicative of CMV infection. The first loading component of partial least squares analysis ranked the contribution of each cytokine to accurate classification; a positive score suggests that the expression of a particular cytokine is indicative of CMV infection.
RESULTS
Cytokine Levels in Amniotic Fluid From Congenital CMV Cases and Uninfected Controls
Levels of cytokines with prominent proinflammatory (Th1) characteristics (TNF-a, IL-1b, IL-12, and IL-17) were significantly elevated in amniotic fluid taken from congenital CMV cases, compared with those in controls, as were levels of chemokines CCL2, CCL4, and CXCL10 (P , .01) ( Table 1 ).
The level of IL-15, which has both proinflammatory and anti-inflammatory properties, was also significantly elevated with congenital CMV infection. The level of the antiinflammatory cytokine IL-4 was significantly lower in amniotic fluid from congenital CMV cases, compared with that in uninfected controls, which is consistent with a shift toward a Th1 cytokine profile with CMV infection. However, levels of the anti-inflammatory cytokines IL-1ra and IL-10 were significantly elevated in amniotic fluid from congenital CMV cases, compared with those in controls, and there were no differences between the 2 groups for another antiinflammatory cytokine, IL-13. The only growth factors with significantly elevated levels in CMV-infected amniotic fluid were GM-CSF and PDGF-bb (Table 1) .
Cytokine Levels in Maternal Sera Taken From Pregnant Women With Primary CMV Infection and Uninfected Controls
Only the CXCL10 level was significantly elevated in maternal sera taken from pregnant women with documented primary CMV infection, compared with the level in uninfected controls (P , .01). The levels of all other cytokines, chemokines, and growth factors were not significantly different between sera from women with and women without CMV infection.
Multivariate Analysis of Cytokine Levels in Amniotic Fluid
Heat map analysis showed distinct differences in the overall cytokine expression profile in CMV-infected and CMVuninfected amniotic fluid (Figure 1) . Almost all patients with CMV-uninfected amniotic fluid formed one group (cluster 1). All patients with CMV-infected amniotic fluid formed a different group (cluster 2); this was interspersed with 7 patients with CMV-uninfected amniotic fluid. Separate heat maps demonstrated that expression of CCL2 did not correlate with expression of other cytokines in amniotic fluid samples where CMV was present (data not shown). Partial least squares analysis showed that CXCL10 was the cytokine most predictive of CMV-infected amniotic fluid, compared with CMV-uninfected amniotic fluid (data not shown).
DISCUSSION
Cytokine profiles in amniotic fluid from CMV-infected pregnancies showed an overall shift toward Th1 dominance at T2, at which time maternofetal CMV transmission has usually occurred. These differences were observed at the individual and global cytokine levels and were confirmed using partial least squares and heat map analyses, respectively. Significantly higher levels of expression of chemokines CCL2, CCL4, and CXCL10, together with proinflammatory cytokines TNF-a, IL-1b, IL-12, and IL-17, and lower levels of antiinflammatory IL-4 in CMV-infected amniotic fluid indicate a strong overall shift toward Th1 bias in CMV-infected amniotic fluid samples. However, greater expression of antiinflammatory IL-1ra and IL-10 and of cytokines with both anti-inflammatory and proinflammatory properties, such as IL-15, suggests the effects of CMV infection in the placenta are complex. The dual influences of cellular antiviral responses and CMV immune escape mechanisms most likely contribute to the observed differences in cytokine expression in CMVinfected samples. The observed cytokine changes would have important consequences for placental structure, placental function, and maintenance of tolerance at the maternal-fetal interface and are likely to affect transplacental CMV transmission [3] . In contrast, our previous studies of amniotic fluid in healthy pregnancies showed a balanced Th1/Th2 cytokine profile during T2 [7] . Routine amniocentesis for pregnant women of advanced maternal age (.35 years) or with previous pregnancy complications at the Royal Hospital for Women is undertaken at 14-16 weeks of gestation, whereas identification and diagnosis of congenital CMV infection cases generally occurs at later gestational age. Hence, the median gestational ages at which amniotic fluid was collected from control cases (15 weeks) was less than that for the 8 congenital CMV cases (19.5 weeks) ( Table 1 ). Rates of congenital CMV infection in Australia are relatively low (0.3% of all live births) [2] , and ethical considerations prevent later collection of control specimens; hence, the difference in gestational ages is difficult to avoid. Our previous analyses showed that cytokine levels do not change significantly from 14 to 18 weeks of gestation, with the exception of the IL-1ra level, which increases moderately as pregnancy progresses [7] . Removal from the analysis of the single amniotic fluid sample taken at 34 weeks of gestation did not alter median cytokine levels for congenital CMV cases, and accordingly this sample was included in all subsequent analyses. All CMV-positive amniotic fluid samples clustered together in heat map analyses, although a small number (7%) of CMV-negative samples also clustered with this group. This suggests that an altered cytokine profiles in amniotic fluid is a good indicator of CMV infection, but factors other than infection may contribute to changes in cytokine levels in some pregnancies. An elevated TNF-a level has been observed in CMVinfected cytotrophoblasts and monocytes in vitro, with subsequent apoptosis of proximal syncytiotrophoblast [3] , and elevated TNF-a has been associated with severe chorioamnionitis in uninfected pregnant women [9] . Higher IL-10 expression in amniotic fluid from CMV-infected pregnancies is also consistent with observations in CMVinfected in vitro cultures, where IL-10 downregulates metalloproteinase expression and limits the invasive capacity of extravillous cytotrophoblasts [3] . Other in vitro studies showed that CMV infection increases IL-6 and CXCL8 production in CMV-infected extravillous trophoblasts and syncytiotrophoblasts preceding cell death [8] . Our results show that the IL-6 level was not significantly higher in amniotic fluid from CMV-infected pregnancies and that the CXCL8 level was not elevated above that observed for uninfected pregnancies.
Inflammation in the placenta in response to CMV infection can have severe consequences for the developing fetus. Our results from T2 amniotic fluids demonstrate that an overall shift toward a proinflammatory state occurs in CMV-infected pregnancies. This proinflammatory bias is enhanced by decreases in levels of some anti-inflammatory cytokines, such as IL-4. Changes in the level of individual cytokines may have different effects on the viability of infected and neighboring cells, placental structure, and maintenance of pregnancy, causing indirect harm and/or promoting virus transmission to the fetus [3] . Prevention of CMV infection and amelioration of the effects of CMV infection when it occurs are the ultimate goals. These data raise the possibility of cytokine modulators as therapeutics for congenital CMV. 
